Nanosilicate scaffolds to regrow facial and skull bone
Official title: Osteoinductive Nanosilicate-Based Biomaterials for In Situ Craniomaxillofacial Bone Regeneration
Funded at Texas Engineering Experiment Station · NIH-11305253 · Data updated 2026-11-12
A new specially designed nanosilicate biomaterial aims to help people with craniofacial bone loss regenerate bone without using high doses of growth-factor drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Engineering Experiment Station NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | February 9, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $554,639 |
| NIH project number | 5R01DE032031-03 |
| Project ID | NIH-11305253 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with significant craniofacial or skull bone defects from trauma, infection, congenital differences, or surgical removal of tumors who may need bone grafting are the likely beneficiaries of this work.
✕Less likely to help
Patients with unrelated conditions, such as purely dental issues, systemic bone diseases that prevent healing, or those requiring major load-bearing long-bone reconstruction, are unlikely to benefit from this specific craniofacial-focused approach.
What this research studies
This project develops mineral-based nanosilicate particles that can encourage human stem cells to become bone-forming cells without adding external growth factors. The team will study how these nanosilicates trigger bone-making signals at the molecular level, then design 3D-printed, microporous scaffolds that release the nanosilicates and support tissue ingrowth. Experiments will use lab-grown human cells and preclinical models to test whether the scaffolds promote safe, localized bone formation. The long-term goal is a minimally invasive biomaterial treatment for rebuilding skull and facial bones after trauma, infection, congenital issues, or tumor removal.
Why it matters
Potential benefit: If successful, this approach could rebuild craniofacial bone while avoiding high-dose growth-factor therapies that can cause dangerous side effects.
How similar studies have gone: Commercial grafts using high-dose growth factors (like BMP2) have clinical use but carry risks, while nanosilicate-only biomaterials are a newer, largely preclinical approach with promising lab and animal results but limited human data.
Where this research is happening
-
Texas Engineering Experiment Station
College Station, United States Active
Researchers
- Principal investigator: Gaharwar, Akhilesh K. — Texas Engineering Experiment Station
- Study coordinator: Gaharwar, Akhilesh K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.